Skip to main content
Premium Trial:

Request an Annual Quote

Incyte, Medarex Announce Deal to Develop Antibody Therapeutics

NEW YORK, Oct. 18 – Incyte Genomics and Medarex said Thursday they would work together to develop and commercialize human antibody therapeutics.

Under the terms of the deal, Medarex and Incyte will share the preclinical and clinical development costs associated with developing antibody products. The two companies said they would also jointly sell and distribute products resulting from the collaboration.

Incyte of Palo Alto, Calif., said it would work from its database of transcribed genes, which includes over 600 patented full-length genes. Recently, Incyte has been expanding the claims of these patents to include the proteins encoded by gene transcripts as well as the antibodies to the proteins.

Medarex of Princeton, NJ, said it would apply its UltiMab Human Antibody Development System for the development of fully human monoclonal antibodies to the disease targets selected by Incyte from its database.

Financial terms of the deal were not disclosed. 

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.